Loading clinical trials...
Loading clinical trials...
Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
Conditions
Interventions
VDMN-21 Patch Low Dose
VDMN-21 Patch High Dose
+1 more
Locations
16
United States
Site 07
Fort Smith, Arkansas, United States
Site 16
San Diego, California, United States
Site 02
Plainfield, Indiana, United States
Site 13
Louisville, Kentucky, United States
Site 15
Baton Rouge, Louisiana, United States
Site 09
New Brighton, Minnesota, United States
Start Date
February 28, 2023
Primary Completion Date
February 25, 2025
Completion Date
February 25, 2025
Last Updated
May 8, 2025
NCT05937672
NCT07016360
NCT04814446
NCT07396714
NCT02750202
NCT00092534
Lead Sponsor
Veradermics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions